SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Surrozen, (SRZN) — Mar 27, 2026

Surrozen, Inc./DE (SRZN) (CIK 0001824893)
Date: March 27, 2026 · CIK: 0001824893 · Accession: 0000000000-26-003144

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-294542

Date
March 27, 2026
Author
Division of
Form
UPLOAD
Company
Surrozen, Inc./DE (SRZN) (CIK 0001824893)

Letter

Re: Surrozen, Inc. Registration Statement on Form S-3 Filed March 23, 2026 File No. 333-294542 Dear Craig Parker:

March 27, 2026

Craig Parker President and Chief Executive Officer Surrozen, Inc. 171 Oyster Point Blvd, Suite 400 South San Francisco, California 94080

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tim Buchmiller at 202-551-3635 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: John T. McKenna, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 27, 2026

Craig Parker
President and Chief Executive Officer
Surrozen, Inc.
171 Oyster Point Blvd, Suite 400
South San Francisco, California 94080

 Re: Surrozen, Inc.
 Registration Statement on Form S-3
 Filed March 23, 2026
 File No. 333-294542
Dear Craig Parker:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Tim Buchmiller at 202-551-3635 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: John T. McKenna, Esq.
</TEXT>
</DOCUMENT>